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Abstract
Background: Binding to Sema4D and PlexinB1 induce angiogenesis and invasive growth in colorectal cancer (CRC).
The expression of Semaphorin4D (Sema4D) and PlexinB1 has been shown to be related to the prognosis of
patients with various malignancies. However, the correlation between the expression of Sema4D and PlexinB1 and
the relapse-free survival in patients with colorectal cancer remains controversial.
Methods: The study population included patients who underwent surgery for colorectal cancer (n = 226). The
expression of Sema4D and PlexinB1 were analyzed by immunohistochemistry in tissue of stage I, II, and III colon
cancers.
Results: The immunohistochemical staining of colorectal cancer tissue specimens revealed that 95 (42 %) and 105
(46.4 %) of the specimens were positive for Sema4D and PlexinB1. The expression of Sema4D and PlexinB1
respectively were both found to be significantly related to stage, depth of tumor invasion, lymph node metastasis,
lymphatic invasion, and venous invasion, respectively. Sixty-three patients (27.9 %) expressed both Sema4D and
PlexinB1. The positive expression of both Sema4D and PlexinB1 was found to be an independent risk factor for a
worse survival (HR 1.079, CI 1.013–2.868; P = 0.044).
Conclusion: The combination of Sema4D and PlexinB1 protein detected by immunohistochemistry was therefore
useful for predicting disease recurrence in CRC patients.
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Background
Worldwide, colorectal cancer (CRC) is the second high-
est cause of deaths among females and the third highest
cause of among males with malignant neoplasms. There
are 1.4 million new cases of CRC worldwide each year;
700,000 of these patients will die from CRC. With the
number of CRC patients increasing each year, CRC will
become the world’s most important malignancy [1].
Surgical resection is performed in most patients in
whom CRC is detected. However, disease recurrence oc-
curs in 20–25 % of patients after a curative operation
[2]. In spite of treatment, most patients with recurrent
CRC progress to death within a relatively short period of
time. In the clinical setting, it is important to prevent
recurrence to prolong survival. It is therefore helpful to
understand the risk factors for recurrence. Shibutani et
al. reported that the combination of the preoperative
level of CEA and CA19-9 was a useful biomarker for re-
currence in CRC patients after a curative operation [3].
The microsatellite instability (MSI) status has been re-
ported to be an independent prognostic predictor of time
to recurrence [4].
In this study, we focused on the Semaphorin4D
(Sema4D) proteins. Semaphorins are a large family of se-
creted, transmembrane or glycosylphosphatidylinositol-
linked proteins which contain a phylogenetically con-
served extracellular “sema” domain. They are classified
into eight classes, of which 3 to 7 contain vertebrate
semaphorins [5, 6]. Sema4D is a transmembrane protein.
Through shedding by membrane type 1-matrix metallo-
proteinase 1 (MT1-MMP), it transforms into a soluble
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form, which mainly binds to PlexinB1 [7]. PlexinB1 is
single-pass transmembrane receptor for Sema4D, which
is mainly expressed on endothelial cells and epithelial
cells [5].
Recently, the role of Sema4D, via interaction with
PlexinB1, in activities such as tumor angiogenesis and
invasive growth have been discussed in relation to vari-
ous types of tumors [8–10]. Thus, in the present study
we investigated the expression of Sema4D and PlexinB1
in CRC tissue specimens and assessed their association
with various clinicopathological factors. Finally, we clari-




The study population included patients who underwent
surgery for colorectal cancer between 2008 and 2011 at
the Department of Surgical Oncology, Osaka City Uni-
versity Graduate School of Medicine, Japan. Patients
who received preoperative chemotherapy were excluded
from the analysis. The patients consisted of 124 males
and 102 females, with a median age of 66 years (range:
21–91 years). The clinicopathological classification was
determined according to the TNM classification of ma-
lignant tumors, as described by the International Union
Against Cancer (UICC) [11]. The tumor stages of the
patients were graded as follows: stage I (n = 58), stage II
(n = 57), and stage III (n = 111).
The immunohistochemical analysis
All tissues were fixed in 10 % formalin immediately after
surgical resection and 6-μm-thick specimens were em-
bedded in paraffin. The immunohistochemical determin-
ation of the Sema4D and PlexinB1 levels in the
colorectal cancer cells was carried out according to the
manufacturer’s instructions. In brief, the slides were
deparaffinized in xylene and hydrated in decreasing con-
centrations of ethyl alcohol. The sections were then
deparaffinized and incubated with 3 % hydrogen perox-
ide in methanol for 15 min to block endogenous perox-
idase activity. The tissues were subsequently heated for
10 min at 105 °C by autoclaving in Target Retrieval Solu-
tion (Dako, Carpinteria, CA, USA). The sections were
then washed in phosphate-buffered saline (PBS) and in-
cubated in 10 % normal rabbit serum for 10 min to re-
duce nonspecific antibody binding. The specimens were
incubated with antibodies to Sema4D for 1 h at room-
temperature and antibodies to PlexinB1 overnight at 4 °C.
They were then washed twice with PBS. The primary anti-
bodies used for the immunohistochemical detection of
anti-Sema4D and anti-PlexinB1 were Rabbit polyclonal
antibody to Sema4D (SIGMA-Aldrich Ltd, Poole, UK,
HPA015662, 1:150) and Rabbit polyclonal antibody to
PlexinB1 (SIGMA-Aldrich Ltd, Poole, UK, HPA040586,
1:100). The sections were incubated with biotinylated
rabbit anti-goat immunoglobulin G for 10 min, then
washed twice with PBS. The slides were then treated with
peroxidase-conjugated streptavidin reagent for 5 min and
washed twice with PBS. Finally, the slides were incubated
with diaminobenzidine (DAB) kit (Histofine SAB-PO Kit;
Nichirei, Tokyo, Japan) for 180 s for Sema4D antibodies,
and 150 s for PlexinB1 antibodies, then counterstained
with Mayer’s hematoxylin and mounted.
The evaluation of immunostaining for Sema4D
We counted the total number of infiltrating inflamma-
tory cells in the tumor stroma in three independent
high-power fields (×400) for each tissue sample. The
positive Sema4D staining of inflammatory cells was ob-
served in the tumor stroma (Fig. 1). We then calculated
the percentage of Sema4D-positive cells among the total
number of inflammatory cells. The specimens were then
divided into three grades, according to the degree of
positivity as follows: grade 1 (0–25 % positive), grade 2
(26–50 % positive) and grade 3 (51–100 % positive). For
Fig. 1 Immunohistochemical staining for Semaphorin4D. The
immunohistochemical evaluation of Sema4D-positive cells in
colorectal cancer specimens. The positive staining of inflammatory
cells was observed in the tumor stroma. a The photograph was
taken at a magnification of ×100, b The photograph was taken at a
magnification of ×400
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the statistical analyses, grades 1 and 2 were defined as
negative, and grade 3 was defined as positive [9].
The evaluation of immunostaining for PlexinB1
Positive PlexinB1 staining of the tumor gland was ob-
served in the cytoplasm of cancer cells (Fig. 2). The
staining intensity of epithelial tumor cells (in compari-
son to non-tumor cells) was scored as follows: 0 (no
staining), 1 (weak staining), 2 (moderate staining) and 3
(strong staining). For the statistical analyses, scores of 0
or 1 were defined as negative, and a score of 2 or 3 was
defined as positive [9].
Statistical analysis
The associations between the expression of Sema4D and
PlexinB1 and various clinicopathological factors were
assessed using the χ2 test or Fisher’s exact test. To inves-
tigate the associations between relapse-free survival and
various clinicopathological factors, a univariate survival
analysis was performed using the Kaplan-Meier method,
and the differences were evaluated using the log-rank
test. A multivariate survival analysis was performed
using Cox’s proportional-hazard model. Hazard ratios
and 95 % confidence intervals were used to measure as-
sociations. The JMP® 10 software program (SAS Institute
Inc., Cary, NC, USA) was used for all of the statistical
analyses. P values of <0.05 were considered to be statisti-
cally significant.
Results
The correlations between Sema4D and PlexinB1
expression and the clinicopathological findings
The immunohistochemical staining of colorectal cancer
tissue specimens revealed that 95 (42 %) and 105
(46.4 %) of the specimens were positive for Sema4D and
Plexin B1, respectively. The expression of Sema4D was
significantly related to stage, the depth of tumor inva-
sion, lymph node metastasis, lymphatic invasion, and
venous invasion (Table 1). Age, gender and histology did
not significantly affect Sema4D expression. The expres-
sion of PlexinB1 was significantly related to stage, depth
of tumor invasion, lymph node metastasis, lymphatic in-
vasion, and venous invasion. There were no significant
differences among the other factors.
The correlations between Sema4D and PlexinB1
expression
Among 85 tumors which were found to be positive for
Sema4D, 63(74.1 %) were positive for PlexinB1. On the
other hand, among the 131 tumors which found to be
negative for Sema4D, 42(32 %) were negative for Plex-
inB1. There was a significant correlation between the ex-
pression of Sema4D and PlexinB1 (p < 0.001, Table 2).
The correlations between positivity for both Sema4D and
PlexinB1 and the clinicopathological findings
Sixty-three patients (27.9 %) expressed both Sema4D
and PlexinB1. There were no significant differences in
the amount of infiltrated inflammatory cells around the
tumor stroma between the positive Sema4D/PlexinB1
group and the negative Sema4D/PlexinB1 group (p =
0.539). We examined the correlations between the posi-
tive expression of both Sema4D and PlexinB1 and the
clinicopathological findings. The expression of both
Sema4D and PlexinB1 was found to be correlated with
all of the clinicopathological factors that were examined,
with the exception of age, gender and histology (Table 3).
In addition, we evaluated the presence of any correlation
between the treatment as an adjuvant chemotherapy and
the expression of Sema4D and PlexinB1. Adjuvant
chemotherapy was administered to patients who
belonged to the high risk groups with stage II and stage
III disease, except for patients who rejected any further
treatment and those who demonstrated a poor perform-
ance status. As a result, no significant differences were
observed between the adjuvant chemotherapy and the
Fig. 2 Immunohistochemical staining for PlexinB1. The
immunohistochemical evaluation of PlexinB1 positive cells in
colorectal cancer. The positive staining of the tumor gland was
observed in the cytoplasm of cancer cells. a The photograph was
taken at a magnification of ×100, b The photograph was taken at a
magnification of ×400
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combination of Sema4D and PlexinB1 expression at each
stage (Table 4).
Measurement of the overall survival and relapse-free
survival
The patients of both Sema4D and PlexinB1 positive
groups exhibited a worse prognosis compared to the
others (p < 0.001, Fig. 3). In the univariate analysis, hist-
ology, the depth of tumor invasion, lymph node
metastasis, lymphatic invasion, venous invasion and
positivity for both Sema4D and PlexinB1 were found to
be significantly associated with overall survival (Table 5).
However, a multivariate analysis demonstrated that
the depth of tumor invasion (HR 2.692, CI 1.022–
9.317; P = 0.044), lymph node metastasis (HR 2.304,
CI 1.138–5.069; P = 0.019), and the positive expression
of both Sema4D and PlexinB1 (HR 1.681, CI 1.004–
2.819; P = 0.047) were an independent risk factors for
worse survival (Table 5). The recurrence rate was 46 %
(29/63) in patients who positively expressed both Sema4D
and PlexinB1, and 16.6 % (27/163) in the other patients;
this amounted to a significant difference (p < 0.001). The
relapse-free survival (RFS) of the patients who positively
expressed both Sema4D and PlexinB1was significantly
worse than that of other patients (p < 0.001, Fig. 4). In the
univariate analysis, histology, the depth of tumor invasion,
lymph node metastasis, lymphatic invasion, venous inva-
sion and positivity for both Sema4D and PlexinB1 were
found to be significantly associated with RFS (Table 6).
Table 1 Correlations between clinicopathological findings and the expression of Sema4D and PlexinB1
Variables Sema4D expression p value PlexinB1 expression p value
Positive Negative Positive Negative
(n = 95) (n = 131) (n = 105) (n = 121)
Age (years)
Mean ± SD 65.2 ± 12.3 67.2 ± 10.5 0.426 67.6 ± 11.0 65.8 ± 11.5 0.23
Gender
Male 51(53.7) 73(55.7) 0.76 56(53.3) 68 0.666
Female 44(46.3) 58(44.3) 49(46.7) 53
Stage
I 15(15.8) 43(32.8) 0.001 16(15.2) 42 <0.001
II 21(22.1) 36(27.5) 19(18.1) 38
III 59(62.1) 52(36.7) 70(66.7) 41
Histology
Well/mod 82(86.3) 120(91.6) 0.206 91 111 0.217
Other 13(13.7) 11(8.4) 14 10
Depth of tumor invasion
T1/T2 18(18.9) 50(38.2) 0.001 20 48 0.006
T3/T4 77(81.1) 81(61.8) 85 73
Lymph node metastasis
negative 37(38.9) 78(59.5) 0.001 35 79 <0.001
positive 58(61.1) 53(40.5) 69 42
Lymphatic invasion
Negative 18(18.9) 66(50.4) <0.001 21 57 <0.001
Positive 77(81.1) 65(49.6) 84 64
Venus invasion
Negative 70(73.7) 117(89.3) <0.001 76 111 <0.001
Positive 25(26.3) 14(10.7) 29 10
Sema4D semaphorin 4D. Other poorly-differnetiated, mucinous-type, small-cell, signet-cell
Table 2 Correlation between Sema4D and PlexinB1 expression
in colorectal cancer
Sema4D positive Sema4D negative
(n = 85) (n = 131)
PlexinB1 positive 63(27.9) 42(18.6)
(n = 105)
PlexinB1 negative 32(14.1) 89(39.4)
(n = 121)
Sema4D semaphorin 4D
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However, a multivariate analysis demonstrated that lymph
node metastasis (HR 2.783, CI 1.425–5.822; P = 0.002),
and the positive expression of both Sema4D and PlexinB1
(HR 1.079, CI 1.013–2.868; P = 0.044) were an independ-
ent risk factors for worse survival (Table 6).
Discussion
The expression of Sema4D and PlexinB1 has been
shown to be related to the prognosis of patients with
various malignancies. Wang et al., reported the expres-
sion of Sema4D to be a novel indicator of a poor prog-
nosis in CRC patients [8]. Kato et al., reported that the
positive expression of both Sema4D and PlexinB1 was
significantly correlated with worse survival in patients
with pancreatic cancer [9].
On the other hand, it was reported that the decreased
expression of Sema4D and PlexinB1 was associated with
local recurrence and poor prognosis in breast cancer
[10]. Although, the expression of Sema4D and PlexinB1
have been investigated in some solid malignancies, the
correlation between the expression of these factors and
the prognosis of patients with malignant tumors remains
controversial.
Angiogenesis and invasive growth are induced through
binding to Sema4D and PlexinB1. Consequently, the
Sema4D and PlexinB1 positivity increases the possibility
of relapse. Two pathways downstream to PlexinB1 have
been reported to be mechanisms which underlie angio-
genesis and invasive growth. The first mechanism is the
transactivation of the tyrosine kinase activity of Met
[12], a tyrosine kinase receptor which mediates invasive
growth [13], the other is the activation of small GTPase
Ras homolog gene family member A (RhoA) [14], Class
Table 4 Correlations between adjuvant chemotherapy and the
combination of Sema4D and PlexinB1 expression
Variables Total Sema4D and PlexinB1
expression
p value
(n = 226) Both positive Others
(n = 63) (n = 163)
Stage I
Adjuvant chemotherapy
Treated 0(0) 0(0) 0(0) -
Untreated 58(100) 7(100) 51(100)
stage II
Adjuvant chemotherapy
Treated 13(22.8) 3(27.3) 10(21.7) 0.698
Untreated 44(77.2) 8(72.7) 36(78.3)
Stage III
Adjuvant chemotherapy
Treated 81(73) 35(77.8) 46(69.7) 0.106
Untreated 30(27) 10(22.2) 20(30.3)
Sema4D semaphorin 4D
Table 3 Correlations between clinicopathological findings and
the combination of Sema4D and PlexinB1 expresion
Variables Sema4D and PlexinB1 expression p value
Both positive Others
(n = 63) (n = 163)
Age (years)
Mean ± SD 68.1 ± 10.2 66.0 ± 11.7 0.351
Gender
Male 35 89 0.897
Female 28 74
Stage




Well/mod 53 149 0.123
Other 10 14
Depth of tumor invasion
T1/T2 10 58 0.002
T3/T4 53 105
Lymph node metastasis
negative 18 96 <0.001
positive 45 67
Lymphatic invasion
Negative 9 69 <0.001
Positive 54 94
Venus invasion
Negative 41 146 <0.001
Positive 22 17
Sema4D semaphorin 4D. Other poorly-differnetiated, mucinous-type,
small-cell, signet-cell
Fig. 3 Kaplan-Meier estimates of over all survival among
colorectal cancer patients with the positive expression of both
Sema4D and PlexinB1
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IV semaphorins promote angiogenesis by stimulating
Rho-initiated pathways through Plexin-B, and the phos-
phorylation of MAPK and Akt [15]. The interaction of
these signal cascades contributes to the progression of
cancer. As a result, the combination of the two mecha-
nisms reflects tumor progression and a worse RFS.
Sema4D can bind to several receptors and induce vari-
ous effects [16]. CD72, a member of the C-type lectin
family, is a low-affinity Sema4D receptor that is
expressed on immune cells, such as B cells, dendritic
cells, macrophages and mast cells. The interaction
between the immune cells promotes the aggregation and
survival of B cells, and enhances the activation of B cells
during antibody production [6]. The high-affinity
Sema4D receptor plexinB1 is mainly expressed on endo-
thelial cells and epithelial cells and promotes their motil-
ity [7, 17]. Plexin B2 receptors have a low-affinity for
Sema4D, and are involved, with the mediation of den-
dritic epidermal T cells, in the wound healing process in
the skin [18, 19]. Thus, Sema4D receptors are located in
various places and have many roles. Above all, PlexinB1
receptors have a high affinity for Sema4D, and contrib-
ute to tumor progression. As a result, it is a factor that
may cause recurrence.
Kato reported the cells expressing Sema4D in the
tumor stroma of pancreatic cancer to be tumor-
infiltrating lymphocytes(mainly T cells and B cells) [9].
In this study, we could not clearly elucidate the cell in
which Sema4D is expressed, although, we consider that
Sema4D is also expressed in the T cells and B cells in
the tumor stroma of colon cancer. It has recently been
hypothesized that Sema4D is involved in the regulation
of the immune response in the tumor microenviron-
ment. Evans et al. demonstrated that Sema4D creates a
barrier to immune infiltration and affects the balance of
regulatory and effector immune cells and signals. These
immunomodulatory functions promote tumor progres-
sion [20]. Thus, there is a possibility that cancers in
which Sema4D and PlexinB1 is expressed have enhanced
Table 5 The results of univariate and multivariate analyses of the expression of Sema4D and PlexinB1, clinicopathological findings
and overall survival in the patients with colorectal cancer
Univariate analysis Multivariate analysis
Variables Hazard ratio 95 % CI p value Hazard ratio 95 % CI p value
Gender 0.928 0.574–1.509 0.762
Male vs. Female
Age 1.365 0.841–2.207 0.205
≧70 vs. <70
Histology 2.666 1.391–4.373 0.004 1.758 0.901–3.205 0.094
Other vs. well/mod
Depth of tumor invasion 4.574 2.032–13.08 <0.001 2.692 1.022–9.317 0.044
T3/T4 vs.T1/T2
Lymph node metastasis 4.469 2.432–9.017 <0.001 2.304 1.138–5.069 0.019
Positive vs. negative
Lymphatic invasion 3.108 1.622–6.725 <0.001 1.318 0.603–3.235 0.505
Positive vs. negative
Venus invasion 2.6 1.554–4.25 <0.001 1.409 0.813–2.394 0.216
Positive vs. negative
Sema4D and PlexinB1 expression 2.567 1.587–4.158 <0.001 1.681 1.004–2.819 0.047
Both positive vs. others
Sema4D semaphorin 4D. Other poorly-differnetiated, mucinous-type, small-cell, signet-cell. CI confidence interval
Fig. 4 Kaplan-Meier estimates of relapse-free survival among
colorectal cancer patients with the positive expression of both
Sema4D and PlexinB1
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invasive capacity through their control of the host im-
mune response and that they may, as a consequence,
cause a relapse.
In this study, the combined expression of Sema4D
and PlexinB1 was found to be an independent risk fac-
tor for disease relapse in the multivariate analysis
(Table 5). Although no significant differences were ob-
served between the adjuvant chemotherapy and the
combination of Sema4D and PlexinB1 expression at
each stage, the relapse-free survival of the patients who
positively expressed both Sema4D and PlexinB1 was
significantly worse than that of other patients (Fig. 3).
As a result, the positive expression of both Sema4D
and PlexinB1 was thus considered to be closely associ-
ated with recurrence. Although the evaluation of the
individual expression of either Sema4D or Plexin-B1
was an indicator of malignant potential [8, 21], it is
thought that the combination of both Sema4D and
PlexinB1 is a more accurate predictor of recurrence in
CRC patients.
While Sema4D and PlexinB1 may represent sensitive
biomarkers for helping to select patients who are at a
high risk of early relapse, our retrospective data analysis
didn’t support attempting to definitively link their expres-
sion to predicting patient outcomes as a function of post-
operative adjuvant chemotherapy (Table 4). Therefore,
further studies on the effects of Sema4D and PlexinB1 are
needed for evaluating their relevance regarding selecting
patients for postoperative adjuvant chemotherapy.
Conclusion
Our results indicated that the detection of the combin-
ation of Sema4D and PlexinB1 was useful for predicting
disease recurrence in CRC patients. However, further
studies will be necessary to more definitively investigate
whether the detection of the combination of Sema4D
and PlexinB1 may be useful for selecting cases in which
postoperative adjuvant chemotherapy will be efficacious
after curative resection.
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